DOCSLIB.ORG

Supplemental Figures

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplemental Figures Defining the elastic fiber interactome Supplemental Information Defining elastic fiber interactions by molecular fishing: an affinity purification and mass spectrometry approach Stuart A. Cain*, Amanda McGovern, Elaine Small, Lyle J. Ward, Clair Baldock, Adrian Shuttleworth and Cay M. Kielty Wellcome Trust Centre for Cell Matrix Research, Faculty of Life Sciences, University of Manchester, United Kingdom. *Corresponding author Supplemental Fig. 1 CPL - + - + - + DTT 250 150 100 75 50 37 Supplemental Fig.1 4-12% bis-Tris gel showing purified calsyntenin-1 (C), proepithelin (P) and LOX (L), with (+) and without (-) reduction with DTT. 1 Defining the elastic fiber interactome SUPPLEMENTAL TABLE 1A Peptides detected no-bait protein controls No-bait protein (bead only) controls were carried out for all four cell compartments Samples were processed as described in the Experimental Procedures, with the exception that no bait protein was added. Scaffold was used to validate protein and peptide identification. Only proteins with >2 unique peptide sequences were counted, and each peptide had greater than 95.0% probability as specified by the Peptide Prophet algorithm (38). Shown is the number of peptides detected,with the number of unique peptide sequence number in brackets. Also shown is the experiment number for which the peptides were detected. Experiments were numbered in the sequence they were conducted and are labelled with the prefix 'ex'. SwissProt Entry ARPE Matrix ARPE Media HDF Matrix HDF Media Protein Protein Identitiy Name ex11 ex169 ex173 ex167 ex171 ex12 ex157 ex158 ex165 ex155 ex163 ex8 Total Fibronectin FINC_HUMAN 2 (2) 2 (2) Histone H3.3 H33_HUMAN 3 (2) 3 (2) Histone H4 H4_HUMAN 12 (7) 12 (7) Keratin, type I cytoskeletal 9 K1C9_HUMAN 9 (8) 9 (8) Keratin, type II cytoskeletal 1 K2C1_HUMAN 7 (7) 7 (7) Lymphoid-restricted membrane protein LRMP_HUMAN 2 (2) 2 (2) Protocadherin-19 PCD19_HUMAN 2(2) 2 (2) Vimentin VIME_HUMAN 14 (13) 14 (13) Grand Total 33 (26) 000002 (2)0016 (15) 0 0 51 (43) SUPPLEMENTAL TABLE 1B Peptides detected cell culture compartment controls Controls were carried out for all four cell compartments Samples were processed as described in the Experimental Procedures, with the exception that no bait protein was added and the samples did not undergo affinity capture LC . Scaffold was used to validate protein and peptide identification. Only proteins with >2 unique peptide sequences were counted, and each peptide had greater than 95.0% probability as specified by the Peptide Prophet algorithm (38). Shown is the number of peptides detected (indicated Pep. No), with the number of unique peptide sequence number in brackets . Also shown is the % coverage for each protein. Protein Identity SwissProt Entry ARPE Matrix ARPE Media HDF Matrix HDF Media Name Pep. No. % Cov Pep. No. % Cov Pep. No. % Cov Pep. No. % Cov Serum albumin ALBU_BOVIN 16 (6) 8.6 118 (20) 29 45 (10) 17 97 (14) 21 Actin, cytoplasmic ACTB_HUMAN 63 (12) 36 15 (5) 18 Vimentin VIME_HUMAN 13 (9) 22 43 (20) 44 Alpha-2-HS-glycoprotein FETUA_BOVIN 2 (2) 4.7 7 (4) 18 10 (4) 11 Serum albumin ALBU_HUMAN 11 (2) 3.1 Keratin, type II cytoskeletal 1 K2C1_HUMAN 6 (4) 12 14 (7) 14 Alpha-1-antiproteinase A1AT_BOVIN 4 (3) 8.4 Keratin, type I cytoskeletal 18 K1C18_HUMAN 13 (8) 18 Keratin, type I cytoskeletal 10 K1C10_HUMAN 6 (3) 6.7 6 (3) 4.7 Histone H4 H4_HUMAN 9 (5) 48 Keratin, type II cytoskeletal 2 epidermal K22E_HUMAN 3 (3) 3.6 Serotransferrin TRFE_BOVIN 5 (4) 4.7 Keratin, type II cytoskeletal 8 K2C8_HUMAN 4 (3) 6.4 Keratin, type II cytoskeletal 7 K2C7_HUMAN 4 (4) 5.1 Heterogeneous nuclear ribonucleoproteins A2/B1 ROA2_BOVIN 3 (2) 12 Supplemental Table 1 2 Defining the elastic fiber interactome SUPPLEMENTAL TABLE 2 Total number of peptides and unique peptide sequences for each protein detected after Scaffold validation Scaffold was used to validate protein and peptide identification. Only proteins with >2 unique peptide sequences were counted and each peptide had greater than 95.0% probability as specified by the Peptide Prophet algorithm (38). The proteins were then ranked by total number of peptides detected. The cell culture compartments in which the identified peptides were detected are also given. Also shown is the number of unique peptide sequence in brackets, and the total % coverage of the unique peptide sequences (calculated as described in Experimental Procedures). Peptides detected from bait proteins were included (shown in bold). The global % ubiquity was calculated for each detected protein using BEPro3. Proteins with a % ubiquity greater than 40% were treated as non-specific contaminants (indicated *). The sequences of the peptides identified for each protein are shown in Supplemental Table 4. Protein Identity SwissProt Entry ARPE Matrix ARPE Media HDF Matrix HDF Media Protein Peptide Total % Ubiquity Name Pep. No. % Cov Pep. No. % Cov Pep. No. % Cov Pep. No. % Cov Pep. No. % Cov Fibrillin-1 FBN1_HUMAN 394 (76) 35.6 760 (115) 55.8 334 (58) 26.6 649 (118) 56.5 2137 (145) 65.8 51.4 Keratin type II cytoskeletal 1 * K2C1_HUMAN 167 (34) 42.9 130 (25) 38.7 154 (32) 41.1 181 (33) 43.6 632 (42) 49.7 86.9 Plasminogen activator inhibitor 1 PAI1_HUMAN 33 (15) 49.3 320 (21) 65.4 2 (2) 6.0 54 (18) 60.4 409 (22) 65.4 38.0 Perlecan PGBM_HUMAN 117 (71) 22.1 256 (96) 31.5 23 (20) 5.5 2 (2) 0.7 398 (113) 36.5 18.6 Keratin type I cytoskeletal 10 * K1C10_HUMAN 96 (32) 54.5 37 (20) 45.7 63 (21) 38.3 123 (31) 52.8 319 (40) 63.9 48.0 Keratin type I cytoskeletal 9 * K1C9_HUMAN 46 (16) 32.3 45 (15) 39.2 63 (14) 30.0 49 (21) 37.9 203 (25) 47.4 50.2 BigH3 BGH3_HUMAN 7 (6) 9.4 123 (23) 47.0 2 (2) 6.0 132 (23) 47.0 7.3 Histone H4. H4_HUMAN 66 (7) 52.4 18 (5) 50.5 32 (7) 52.4 12 (4) 42.7 128 (7) 52.4 14.6 Fibronectin FINC_HUMAN 2 (2) 0.7 57 (37) 23.6 26 (24) 14.8 19 (16) 10.2 104 (49) 30.6 17.8 Stanniocalcin-2 STC2_HUMAN 8 (6) 27.5 44 (6) 27.5 6 (6) 27.5 45 (6) 24.8 103 (7) 30.1 38.2 Thrombospondin-1 TSP1_HUMAN 93 (28) 33.2 5 (4) 6.0 98 (28) 33.2 2.0 Proepithelin GRN_HUMAN 21 (11) 21.8 46 (15) 32.2 5 (4) 9.6 17 (9) 16.5 89 (19) 34.2 8.2 Keratin type II * K22E_HUMAN 15 (18) 20.0 6 (9) 15.8 25 (22) 30.1 41 (27) 35.0 87 (36) 45.0 48.6 Sulfhydryl oxidase 1 QSOX1_HUMAN 67 (28) 47.8 5 (4) 8.3 72 (29) 50.3 0.4 Serum albumin ALBU_HUMAN 10 (7) 11.2 15 (5) 8.7 18 (8) 12.0 22 (8) 13.1 65 (12) 18.2 22.2 Collagen alpha-1(XVIII) chain COIA1_HUMAN 26 (10) 7.4 36 (13) 11.3 62 (15) 13.0 3.4 Lamin-A/C LMNA_HUMAN 17 (8) 14.6 42 (17) 31.6 59 (19) 34.5 8.1 Calsyntenin-1 CSTN1_HUMAN 29 (16) 19.9 16 (14) 18.1 45 (19) 24.1 2.9 Agrin AGRIN_HUMAN 42 (21) 12.8 42 (21) 12.8 6.4 Collagen alpha-1(I) chain CO1A1_HUMAN 5 (4) 4.6 36 (21) 24.1 41 (22) 25.3 11.4 Insulin-like growth factor-binding protein 7 IBP7_HUMAN 2 (2) 10.6 38 (11) 51.8 40 (11) 51.8 0.4 Keratin type I cytoskeletal 14 K1C14_HUMAN 2 (10) 10.0 2 (3) 7.4 15 (16) 26.1 18 (14) 24.2 37 (25) 38.1 8.7 Collagen alpha-1(IV) chain CO4A1_HUMAN 30 (8) 7.5 5 (4) 3.5 35 (8) 7.5 0.3 Insulin-like growth factor-binding protein 4 IBP4_HUMAN 2 (2) 11.2 30 (7) 31.0 32 (7) 31.0 0.4 MAGP-1 MFAP2_HUMAN 2 (2) 9.8 13 (5) 25.1 17 (6) 35.5 32 (6) 35.5 4.1 Collagen alpha-2(IV) chain CO4A2_HUMAN 31 (13) 16.1 0.0 31 (13) 16.1 0.4 Calsyntenin-2 CSTN2_HUMAN 30 (16) 21.4 30 (16) 21.4 2.3 Collagen alpha-2(I) chain CO1A2_HUMAN 28 (18) 23.4 28 (18) 23.4 3.3 Annexin A2 ANXA2_HUMAN 2 (2) 5.6 24 (15) 50.7 26 (15) 50.7 4.2 Keratin type II cytoskeletal 6 K2C6A_HUMAN 5 (4) 14.4 15 (12) 31.4 6 (4) 19.5 26 (20) 43.1 7.5 Insulin-like growth factor-binding protein 3 IBP3_HUMAN 21 (7) 24.4 4 (3) 13.1 25 (7) 24.4 5.4 TGF beta-2 TGFB2_HUMAN 3 (3) 8.5 22 (10) 30.9 25 (10) 30.9 0.6 Histone H2B H2B1M_HUMAN 18 (5) 52.4 4 (3) 27.8 2 (2) 15.9 24 (6) 52.4 2.4 Keratin type II cytoskeletal 5 K2C5_HUMAN 3 (3) 12.5 3 (3) 14.6 16 (14) 26.1 22 (14) 33.2 7.4 Retinoic acid receptor responder protein 2 RARR2_HUMAN 22 (5) 39.3 22 (5) 39.3 1.7 Myosin-9 MYH9_HUMAN 16 (12) 8.8 2 (2) 1.4 3 (3) 1.9 21 (13) 9.5 0.4 Protein NOV homolog NOV_HUMAN 21 (9) 36.1 21 (9) 36.1 0.4 Extracellular matrix protein 1 ECM1_HUMAN 20 (11) 29.1 20 (11) 29.1 0.3 Histone H2A type 2-A H2A2A_HUMAN 11 (4) 59.2 6 (4) 35.4 2 (2) 12.3 19 (5) 67.7 0.4 Collagen alpha-1(XII) chain COCA1_HUMAN 18 (15) 6.4 18 (15) 6.4 0.4 Titin TITIN_HUMAN 3 (3) 0.2 11 (11) 0.7 2 (2) 0.1 16 (16) 0.9 0.4 Keratin type I cytoskeletal K1C16_HUMAN 15 (10) 33.8 15 (10) 33.8 7.5 Supplemental Table 2 3 Defining the elastic fiber interactome Protein Identity SwissProt Entry ARPE Matrix ARPE Media HDF Matrix HDF Media Protein Peptide Total % Ubiquity Name Pep.
Load more

Recommended publications
  • ENSG Gene Encodes Effector TCR Pathway Costimulation Inhibitory/Exhaustion Synapse/Adhesion Chemokines/Receptors
    ENSG Gene Encodes Effector TCR pathway Costimulation Inhibitory/exhaustion Synapse/adhesion Chemokines/receptors ENSG00000111537 IFNG IFNg x ENSG00000109471 IL2 IL-2 x ENSG00000232810 TNF TNFa x ENSG00000271503 CCL5 CCL5 x x ENSG00000139187 KLRG1 Klrg1 x ENSG00000117560 FASLG Fas ligand x ENSG00000121858 TNFSF10 TRAIL x ENSG00000134545 KLRC1 Klrc1 / NKG2A x ENSG00000213809 KLRK1 Klrk1 / NKG2D x ENSG00000188389 PDCD1 PD-1 x x ENSG00000117281 CD160 CD160 x x ENSG00000134460 IL2RA IL-2 receptor x subunit alpha ENSG00000110324 IL10RA IL-10 receptor x subunit alpha ENSG00000115604 IL18R1 IL-18 receptor 1 x ENSG00000115607 IL18RAP IL-18 receptor x accessory protein ENSG00000081985 IL12RB2 IL-12 receptor x beta 2 ENSG00000186810 CXCR3 CXCR3 x x ENSG00000005844 ITGAL CD11a x ENSG00000160255 ITGB2 CD18; Integrin x x beta-2 ENSG00000156886 ITGAD CD11d x ENSG00000140678 ITGAX; CD11c x x Integrin alpha-X ENSG00000115232 ITGA4 CD49d; Integrin x x alpha-4 ENSG00000169896 ITGAM CD11b; Integrin x x alpha-M ENSG00000138378 STAT4 Stat4 x ENSG00000115415 STAT1 Stat1 x ENSG00000170581 STAT2 Stat2 x ENSG00000126561 STAT5a Stat5a x ENSG00000162434 JAK1 Jak1 x ENSG00000100453 GZMB Granzyme B x ENSG00000145649 GZMA Granzyme A x ENSG00000180644 PRF1 Perforin 1 x ENSG00000115523 GNLY Granulysin x ENSG00000100450 GZMH Granzyme H x ENSG00000113088 GZMK Granzyme K x ENSG00000057657 PRDM1 Blimp-1 x ENSG00000073861 TBX21 T-bet x ENSG00000115738 ID2 ID2 x ENSG00000176083 ZNF683 Hobit x ENSG00000137265 IRF4 Interferon x regulatory factor 4 ENSG00000140968 IRF8 Interferon
    [Show full text]
  • Targeted Genes and Methodology Details for Neuromuscular Genetic Panels
    Targeted Genes and Methodology Details for Neuromuscular Genetic Panels Reference transcripts based on build GRCh37 (hg19) interrogated by Neuromuscular Genetic Panels Next-generation sequencing (NGS) and/or Sanger sequencing is performed Motor Neuron Disease Panel to test for the presence of a mutation in these genes. Gene GenBank Accession Number Regions of homology, high GC-rich content, and repetitive sequences may ALS2 NM_020919 not provide accurate sequence. Therefore, all reported alterations detected ANG NM_001145 by NGS are confirmed by an independent reference method based on laboratory developed criteria. However, this does not rule out the possibility CHMP2B NM_014043 of a false-negative result in these regions. ERBB4 NM_005235 Sanger sequencing is used to confirm alterations detected by NGS when FIG4 NM_014845 appropriate.(Unpublished Mayo method) FUS NM_004960 HNRNPA1 NM_031157 OPTN NM_021980 PFN1 NM_005022 SETX NM_015046 SIGMAR1 NM_005866 SOD1 NM_000454 SQSTM1 NM_003900 TARDBP NM_007375 UBQLN2 NM_013444 VAPB NM_004738 VCP NM_007126 ©2018 Mayo Foundation for Medical Education and Research Page 1 of 14 MC4091-83rev1018 Muscular Dystrophy Panel Muscular Dystrophy Panel Gene GenBank Accession Number Gene GenBank Accession Number ACTA1 NM_001100 LMNA NM_170707 ANO5 NM_213599 LPIN1 NM_145693 B3GALNT2 NM_152490 MATR3 NM_199189 B4GAT1 NM_006876 MYH2 NM_017534 BAG3 NM_004281 MYH7 NM_000257 BIN1 NM_139343 MYOT NM_006790 BVES NM_007073 NEB NM_004543 CAPN3 NM_000070 PLEC NM_000445 CAV3 NM_033337 POMGNT1 NM_017739 CAVIN1 NM_012232 POMGNT2
    [Show full text]
  • PFN2, a Novel Marker of Unfavorable Prognosis, Is a Potential Therapeutic
    Cui et al. J Transl Med (2016) 14:137 DOI 10.1186/s12967-016-0884-y Journal of Translational Medicine RESEARCH Open Access PFN2, a novel marker of unfavorable prognosis, is a potential therapeutic target involved in esophageal squamous cell carcinoma Xiao‑bin Cui1,2†, Shu‑mao Zhang1†, Yue‑xun Xu3, Hong‑wei Dang1, Chun‑xia Liu1, Liang‑hai Wang1, Lan Yang1, Jian‑ming Hu1, Wei‑hua Liang1, Jin‑fang Jiang1, Na Li4, Yong Li5*, Yun‑zhao Chen1* and Feng Li1,2* Abstract Background: Esophageal squamous cell carcinoma (ESCC) is one of the most aggressively malignant tumors with dismal prognosis. Profilin 2 (PFN2) is an actin-binding protein that regulates the dynamics of actin polymerization and plays a key role in cell motility. Recently, PFN2 have emerged as significant regulators of cancer processes. However, the clinical significance and biological function of PFN2 in ESCC remain unclear. Methods: PFN2 protein expression was validated by immunohistochemistry (IHC) on tissue microarray from Chinese Han and Kazakh populations with ESCC. The associations among PFN2 expression, clinicopathological features, and prognosis of ESCC were analyzed. The effects on cell proliferation, invasion and migration were examined using MTT and Transwell assays. Markers of epithelial–mesenchymal transition (EMT) were detected by Western blot analysis. Results: Compared with normal esophageal epithelium (NEE), PFN2 protein expression was markedly increased in low-grade intraepithelial neoplasia (LGIN), high-grade intraepithelial neoplasia (HGIN), and ESCC, increased gradually from LGIN to ESCC, and finally reached high grade in HGIN in the Han population. Similarly, PFN2 protein was more overexpressed in ESCC than in NEE in the Kazakh population.
    [Show full text]
  • MARK4 with an Alzheimer's Disease-Related Mutation Promotes
    bioRxiv preprint doi: https://doi.org/10.1101/2020.05.20.107284; this version posted May 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. MARK4 with an Alzheimer’s disease-related mutation promotes tau hyperphosphorylation directly and indirectly and exacerbates neurodegeneration Toshiya Obaa, Taro Saitoa,b, Akiko Asadaa,b, Sawako Shimizua, Koichi M. Iijimac,d and Kanae Andoa,b, * aGraduate School of Science, Tokyo Metropolitan University, Tokyo 192-0397, Japan, bDepartment of Biological Sciences, School of Science, Tokyo Metropolitan University, Tokyo 192-0397, Japan, cDepartment of Alzheimer’s Disease Research, National Center for Geriatrics and Gerontology, Obu, Aichi 474-8511, Japan, dDepartment of Experimental Gerontology, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi 467-8603, Japan *Corresponding author Kanae Ando, Ph.D. E-mail: [email protected] Running title: Mutant MARK4 enhances phospho-tau accumulation Abstract Accumulation of the microtubule-associated protein tau is associated with Alzheimer’s disease (AD). In AD brain, tau is abnormally phosphorylated at many sites, and phosphorylation at Ser262 and Ser356 play critical roles in tau accumulation and toxicity. Microtubule-affinity regulating kinase 4 (MARK4) phosphorylates tau at those sites, and a double de novo mutation in the linker region of MARK4, ΔG316E317InsD, is associated with an elevated risk of AD. However, it remains unclear how this mutation affects phosphorylation, aggregation, and accumulation of tau and tau-induced neurodegeneration. Here, we report that MARK4ΔG316E317D increases the abundance of highly phosphorylated, insoluble tau species and exacerbates neurodegeneration via Ser262/356-dependent and -independent mechanisms.
    [Show full text]
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • Human FGFBP1 ELISA Kit (ARG82056)
    Product datasheet [email protected] ARG82056 Package: 96 wells Human FGFBP1 ELISA Kit Store at: 4°C Summary Product Description Human FGFBP1 ELISA Kit is an Enzyme Immunoassay kit for the quantification of Human FGFBP1 in serum, plasma and cell culture supernatants. Tested Reactivity Hu Tested Application ELISA Target Name FGFBP1 Conjugation HRP Conjugation Note Substrate: TMB and read at 450 nm. Sensitivity 11.7 pg/ml Sample Type Serum, plasma and cell culture supernatants. Standard Range 23.4 - 1500 pg/ml Sample Volume 100 µl Alternate Names Fibroblast growth factor-binding protein 1; 17 kDa heparin-binding growth factor-binding protein; FGF- BP; FGF-binding protein 1; HBp17; FGFBP; 17 kDa HBGF-binding protein; FGFBP-1; HBP17; FGF-BP1 Application Instructions Assay Time 4.5 hours Properties Form 96 well Storage instruction Store the kit at 2-8°C. Keep microplate wells sealed in a dry bag with desiccants. Do not expose test reagents to heat, sun or strong light during storage and usage. Please refer to the product user manual for detail temperatures of the components. Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol FGFBP1 Gene Full Name fibroblast growth factor binding protein 1 Background This gene encodes a secreted fibroblast growth factor carrier protein. The encoded protein plays a critical role in cell proliferation, differentiation and migration by binding to fibroblast growth factors and potentiating their biological effects on target cells. The encoded protein may also play a role in tumor growth as an angiogenic switch molecule, and expression of this gene has been associated with several types of cancer including pancreatic and colorectal adenocarcinoma.
    [Show full text]
  • A Feed-Forward Cycle
    GMJ.2020;9:e1681 www.gmj.ir Received 2019-08-08 Revised 2019-11-11 Accepted 2019-11-24 Tau Abnormalities and Autophagic Defects in Neurodegenerative Disorders; A Feed-forward Cycle Nastaran Samimi 1, 2, Akiko Asada 3, 4, Kanae Ando 3, 4 1 Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran 2 Department of Brain and Cognitive Sciences, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran 3 Department of Biological Sciences, School of Science, Tokyo Metropolitan University, Tokyo, Japan 4 Graduate School of Science, Tokyo Metropolitan University, Tokyo, Japan Abstract Abnormal deposition of misfolded proteins is a neuropathological characteristic shared by many neurodegenerative disorders including Alzheimer’s disease (AD). Generation of excessive amounts of aggregated proteins and impairment of degradation systems for misfolded proteins such as autophagy can lead to accumulation of proteins in diseased neurons. Molecules that contribute to both these effects are emerging as critical players in disease pathogenesis. Furthermore, impairment of autophagy under disease conditions can be both a cause and a consequence of abnormal protein accumulation. Specifically, disease-causing proteins can impair autophagy, which further enhances the accumulation of abnormal proteins. In this short review, we focus on the relationship between the microtubule-associated protein tau and autophagy to highlight a feed-forward mechanism in disease pathogenesis. [GMJ.2020;9:e1681] DOI:10.31661/gmj.v9i0.1681 Keywords: Neurodegenerative Diseases; Tauopathy; Autophagy; Microtubule Binding Pro- tein; Tau; Phosphorylation; Vesicle Trafficking Tau phosphorylation in physiology and dis- However, tau detaches from microtubules and ease misfolds to form insoluble filaments in neuro- isfolded tau protein is deposited in a fibrillary tangles in the brains of patients with Mgroup of neurodegenerative diseases tauopathies [4-9].
    [Show full text]
  • Screening for Copy Number Variation in Genes Associated with the Long QT Syndrome Clinical Relevance
    Journal of the American College of Cardiology Vol. 57, No. 1, 2011 © 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.08.621 Heart Rhythm Disorders Screening for Copy Number Variation in Genes Associated With the Long QT Syndrome Clinical Relevance Julien Barc, PHD,*‡§ François Briec, MD,*†‡§ Sébastien Schmitt, MD,ʈ Florence Kyndt, PharmD, PHD,*‡§ʈ Martine Le Cunff, BS,*‡§ Estelle Baron, BS,*‡§ Claude Vieyres, MD,¶ Frédéric Sacher, MD,# Richard Redon, PHD,*‡§ Cédric Le Caignec, MD, PHD,*‡§ʈ Hervé Le Marec, MD, PHD,*†‡§ Vincent Probst, MD, PHD,*†‡§ Jean-Jacques Schott, PHD*†‡§ Nantes, Angoulême, and Bordeaux, France Objectives The aim of this study was to investigate, in a set of 93 mutation-negative long QT syndrome (LQTS) probands, the frequency of copy number variants (CNVs) in LQTS genes. Background LQTS is an inherited cardiac arrhythmia characterized by a prolonged heart rate–corrected QT (QTc) interval as- sociated with sudden cardiac death. Recent studies suggested the involvement of duplications or deletions in the occurrence of LQTS. However, their frequency remains unknown in LQTS patients. Methods Point mutations in KCNQ1, KCNH2, and SCN5A genes were excluded by denaturing high-performance liquid chromatography or direct sequencing. We applied Multiplex Ligation-dependent Probe Amplification (MLPA) to detect CNVs in exons of these 3 genes. Abnormal exon copy numbers were confirmed by quantitative multiplex PCR of short fluorescent fragment (QMPSF). Array-based comparative genomic hybridization (array CGH) analysis was performed using Agilent Human Genome 244K Microarrays to further map the genomic rearrangements.
    [Show full text]
  • Human Placenta Exosomes: Biogenesis, Isolation, Composition, and Prospects for Use in Diagnostics
    International Journal of Molecular Sciences Review Human Placenta Exosomes: Biogenesis, Isolation, Composition, and Prospects for Use in Diagnostics Evgeniya E. Burkova 1,* , Sergey E. Sedykh 1,2 and Georgy A. Nevinsky 1,2 1 SB RAS Institute of Chemical Biology and Fundamental Medicine, 630090 Novosibirsk, Russia; [email protected] (S.E.S.); [email protected] (G.A.N.) 2 Department of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia * Correspondence: [email protected]; Tel.: +7-(383)-363-51-27 Abstract: Exosomes are 40–100 nm nanovesicles participating in intercellular communication and transferring various bioactive proteins, mRNAs, miRNAs, and lipids. During pregnancy, the placenta releases exosomes into the maternal circulation. Placental exosomes are detected in the maternal blood even in the first trimester of pregnancy and their numbers increase significantly by the end of pregnancy. Exosomes are necessary for the normal functioning of the placenta and fetal development. Effects of exosomes on target cells depend not only on their concentration but also on their intrinsic components. The biochemical composition of the placental exosomes may cause various complications of pregnancy. Some studies relate the changes in the composition of nanovesicles to placental dysfunction. Isolation of placental exosomes from the blood of pregnant women and the study of protein, lipid, and nucleic composition can lead to the development of methods for early diagnosis of pregnancy pathologies. This review describes the biogenesis of exosomes, methods Citation: Burkova, E.E.; Sedykh, S.E.; of their isolation, analyzes their biochemical composition, and considers the prospects for using Nevinsky, G.A. Human Placenta exosomes to diagnose pregnancy pathologies.
    [Show full text]
  • Defining Functional Interactions During Biogenesis of Epithelial Junctions
    ARTICLE Received 11 Dec 2015 | Accepted 13 Oct 2016 | Published 6 Dec 2016 | Updated 5 Jan 2017 DOI: 10.1038/ncomms13542 OPEN Defining functional interactions during biogenesis of epithelial junctions J.C. Erasmus1,*, S. Bruche1,*,w, L. Pizarro1,2,*, N. Maimari1,3,*, T. Poggioli1,w, C. Tomlinson4,J.Lees5, I. Zalivina1,w, A. Wheeler1,w, A. Alberts6, A. Russo2 & V.M.M. Braga1 In spite of extensive recent progress, a comprehensive understanding of how actin cytoskeleton remodelling supports stable junctions remains to be established. Here we design a platform that integrates actin functions with optimized phenotypic clustering and identify new cytoskeletal proteins, their functional hierarchy and pathways that modulate E-cadherin adhesion. Depletion of EEF1A, an actin bundling protein, increases E-cadherin levels at junctions without a corresponding reinforcement of cell–cell contacts. This unexpected result reflects a more dynamic and mobile junctional actin in EEF1A-depleted cells. A partner for EEF1A in cadherin contact maintenance is the formin DIAPH2, which interacts with EEF1A. In contrast, depletion of either the endocytic regulator TRIP10 or the Rho GTPase activator VAV2 reduces E-cadherin levels at junctions. TRIP10 binds to and requires VAV2 function for its junctional localization. Overall, we present new conceptual insights on junction stabilization, which integrate known and novel pathways with impact for epithelial morphogenesis, homeostasis and diseases. 1 National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK. 2 Computing Department, Imperial College London, London SW7 2AZ, UK. 3 Bioengineering Department, Faculty of Engineering, Imperial College London, London SW7 2AZ, UK. 4 Department of Surgery & Cancer, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • 1 Metabolic Dysfunction Is Restricted to the Sciatic Nerve in Experimental
    Page 1 of 255 Diabetes Metabolic dysfunction is restricted to the sciatic nerve in experimental diabetic neuropathy Oliver J. Freeman1,2, Richard D. Unwin2,3, Andrew W. Dowsey2,3, Paul Begley2,3, Sumia Ali1, Katherine A. Hollywood2,3, Nitin Rustogi2,3, Rasmus S. Petersen1, Warwick B. Dunn2,3†, Garth J.S. Cooper2,3,4,5* & Natalie J. Gardiner1* 1 Faculty of Life Sciences, University of Manchester, UK 2 Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK 3 Centre for Endocrinology and Diabetes, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, UK 4 School of Biological Sciences, University of Auckland, New Zealand 5 Department of Pharmacology, Medical Sciences Division, University of Oxford, UK † Present address: School of Biosciences, University of Birmingham, UK *Joint corresponding authors: Natalie J. Gardiner and Garth J.S. Cooper Email: [email protected]; [email protected] Address: University of Manchester, AV Hill Building, Oxford Road, Manchester, M13 9PT, United Kingdom Telephone: +44 161 275 5768; +44 161 701 0240 Word count: 4,490 Number of tables: 1, Number of figures: 6 Running title: Metabolic dysfunction in diabetic neuropathy 1 Diabetes Publish Ahead of Print, published online October 15, 2015 Diabetes Page 2 of 255 Abstract High glucose levels in the peripheral nervous system (PNS) have been implicated in the pathogenesis of diabetic neuropathy (DN). However our understanding of the molecular mechanisms which cause the marked distal pathology is incomplete. Here we performed a comprehensive, system-wide analysis of the PNS of a rodent model of DN.
    [Show full text]